{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:49:27Z","timestamp":1782949767444,"version":"3.54.5"},"reference-count":27,"publisher":"Microbiology Society","issue":"7","funder":[{"name":"Beijing Public Health Experts Project","award":["2022-3-040"],"award-info":[{"award-number":["2022-3-040"]}]},{"name":"Beijing Tongzhou Municipal Science & Technology commission","award":["KJ2022CX044"],"award-info":[{"award-number":["KJ2022CX044"]}]},{"name":"Tongzhou Yunhe Project under Grant","award":["YH201917"],"award-info":[{"award-number":["YH201917"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:p>\n                  <jats:bold>Introduction.<\/jats:bold> Pre-existing fluoroquinolones (FQs) resistance is a major threat in treating multidrug-resistant (MDR) tuberculosis. Sitafloxacin (Sfx) is a new broad-spectrum FQ.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Hypothesis.<\/jats:bold> Sfx is more active against drug-resistant <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb) isolates.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Aim.<\/jats:bold> To determine whether there is cross-resistance between Sfx and ofloxacin (Ofx), levofloxacin (Lfx) and moxifloxacin (Mfx) in MDR Mtb.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods.<\/jats:bold> A total of 106 clinical Mtb isolates, including 23 pan-susceptible and 83 MDR strains, were analysed for Sfx, Lfx and Mfx resistance using MIC assay. The isolates were also subjected to whole-genome sequencing to analyse drug-resistant genes.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results.<\/jats:bold> Sfx exhibited the most robust inhibition activity against Mtb clinical isolates, with a MIC<jats:sub>50<\/jats:sub> of 0.0313 \u00b5g ml<jats:sup>\u22121<\/jats:sup> and MIC<jats:sub>90<\/jats:sub> of 0.125 \u00b5g ml<jats:sup>\u22121<\/jats:sup>, which was lower than that of Mfx (MIC<jats:sub>50<\/jats:sub> = 0.0625 \u00b5g ml<jats:sup>\u22121<\/jats:sup>, MIC<jats:sub>90<\/jats:sub> = 1 \u00b5g ml<jats:sup>\u22121<\/jats:sup>) and Lfx (MIC<jats:sub>50<\/jats:sub> = 0.125 \u00b5g ml<jats:sup>\u22121<\/jats:sup>, MIC<jats:sub>90<\/jats:sub> = 2 \u00b5g ml<jats:sup>\u22121<\/jats:sup>). We determined the tentative epidemiological cut-off values as 0.5 \u00b5g ml<jats:sup>\u22121<\/jats:sup> for Sfx. Also, 8.43% (7\/83), 43.37% (36\/83), 42.17% (35\/83) and 51.81% (43\/83) MDR strains were resistant to Sfx, Mfx, Lfx and Ofx, respectively. Cross-resistance between Ofx, Lfx and Mfx was 80.43% (37\/46). Only 15.22% (7\/46) of the pre-existing FQs resistance isolates were resistant to Sfx. Among the 30 isolates with mutations in <jats:italic>gyrA<\/jats:italic> or <jats:italic>gyrB<\/jats:italic>, 5 (16.67%) were Sfx resistant. The combination of Sfx and rifampicin could exert partial synergistic effects, and no antagonism between Sfx and six clinically important anti-Mtb antibiotics was evident.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusion.<\/jats:bold> Sfx exhibited superior activity against MDR isolates comparing to Lfx and Mfx, and could potentially overcome the majority pre-existing FQs resistance in Mtb strains.<\/jats:p>","DOI":"10.1099\/jmm.0.001825","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T13:17:24Z","timestamp":1721395044000},"source":"Crossref","is-referenced-by-count":7,"title":["New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis"],"prefix":"10.1099","volume":"73","author":[{"given":"Qing","family":"Sun","sequence":"first","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pharmacy of Beijing Chest Hospital, Capital Medical University, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Liao","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Administration Office of Clinical Trial, Beijing Chest Hospital, Capital Medical University, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqian","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Dong","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglu","family":"Jiang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Huang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyong","family":"Guo","sequence":"additional","affiliation":[{"name":"Pharmacy of Beijing Chest Hospital, Capital Medical University, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","volume-title":"Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","year":"2019"},{"key":"R2","volume-title":"Global Tuberculosis Report 2021","year":"2021"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00409-21"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.02.004"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0814"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3270-3272.2001"},{"key":"R7","first-page":"8135","article-title":"In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii","volume":"8","author":"Dong","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.12.014"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf218"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16720"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S321969"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw147"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108789"},{"key":"R14","volume-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard, CLSI Document M62","year":"2018"},{"key":"R15","volume-title":"Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB","year":"2018"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2002.0973"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp336"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000493"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00825-17"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.848"},{"key":"R22","volume-title":"Technical report on the pharmacokinetics and pharmacodynamics (Pk\/Pd) of medicines used in the treatment of drug-resistant tuberculosis","year":"2018"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr566"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa496"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02775-15"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.01.007"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1007\/s002849900095"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001825?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T13:17:39Z","timestamp":1721395059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.001825","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]}}}